RxDoctor Payments Data

Gary Gregerson, MD

Obstetrics & Gynecology · Nampa, IDNPI 1801834866

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,150 of the $7,578 with a category attached, or 68.0%. Astellas Pharma US Inc accounts for 68.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $5,198 and has fallen 98.8% since, to $62 in 2025.

$7,578in general payments, 2019–2025

Across 39 payments — averaging $194.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$5K
  • Pfizer$2K
  • AbbVie$194
  • Boston Scientific$68
  • Lilly USA, LLC$66
  • Novo Nordisk$57
  • plus $213 from 12 others
$1,911,124in research payments, 2019–2025

Across 529 payments — averaging $3612.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$731K
  • GSK$543K
  • Pfizer$482K
  • Evofem Biosciences, Inc.$150K
  • Sun Pharmaceutical Industries Inc.$5K

What the payments were for

  • Speaking & faculty fees$5,15068%
  • Travel & lodging$1,16015%
  • Food & beverage$1,26817%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,578 in reported general payments places this provider in the 85th percentile of 166 obstetrics & gynecology providers in Idaho.

See all obstetrics & gynecology providers in Idaho

Medicare billing

Part B allowed, 2024
$26,518
Medicare patients
81
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$28,540
ProgesteroneProgesterone, Micronized37$1,455
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$208
Losartan Potassium15$158
Omeprazole12$121
Ropinirole Hcl14$108
Levothyroxine Sodium20$96
Montelukast Sodium12$62
Metformin Hcl13$60
Estradiol26$60
Atorvastatin Calcium15$58
Gabapentin11$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$66$28,54027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 166 obstetrics & gynecology providers in Idaho.

Other obstetrics & gynecology in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →